Key result
In 71 pediatric patients with Ewing sarcoma treated with anthracyclines, 21 (30%) developed an ejection fraction <50%, with younger age, low BMI, and IV push administration as risk factors.
Why the study?
What is the incidence and what are the risk factors for anthracycline-induced cardiotoxicity in pediatric patients with Ewing sarcoma?
Population
71 patients age <17 years, diagnosed with Ewing sarcoma during 1978-2006, treated at British Columbia…
Design
Cohort
Follow-up
Median time to worst cardiac function 51 months
Authors
Loading...
High cardiotoxicity incidence supports monitoring in pediatric Ewing sarcoma; leaves open whether targeting age, BMI, or infusion rate improves outcomes.
Cohort (n=71)
No
What is the incidence and what are the risk factors for anthracycline-induced cardiotoxicity in pediatric patients with Ewing sarcoma?
Pediatric patients with Ewing sarcoma treated with anthracyclines have a high incidence of cardiotoxicity, with progressive decline in cardiac function often noted post-therapy.
Brown et al. (2013) conducted a cohort in Ewing sarcoma (n=71). Anthracycline chemotherapy was evaluated on Ejection fraction < 50%. In 71 pediatric patients with Ewing sarcoma treated with anthracyclines, 21 (30%) developed an ejection fraction <50%, with younger age, low BMI, and IV push administration as risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: